Lu, Tianqi
Lahousse, Lies
Wijnant, Sara
Chen, Jinluan
Brusselle, Guy G.
van Hoek, Mandy
Zillikens, M. Carola
Funding for this research was provided by:
FWO Senior research project fundamental research (G060423N)
Article History
Received: 4 September 2023
Accepted: 22 January 2024
First Online: 9 February 2024
Declarations
:
: The Rotterdam Study (RS) has been approved by Erasmus MC Medical Ethics Committee (registration number MEC 02.1015), executed by the Dutch Ministry of Health, Welfare and Sports (Population Screening Act WBO, license number 1071272-159521-PG).
: All participants gave written informed consent.
: M. C. Zillikens reports steering committee member of ERN BOND (European reference network for rare bone conditions); Committees for scientific bone societies ECTS and ASBMR unpaid; Member of International XLH register, unpaid. M. van Hoek reports Bureau Prevents for a total of 3 educational lectures on cardiovascular risk, obesity and diabetes. L. Lahousse reports expert consultation for AstraZeneca, paid to institution; Lectures for IPSA vzw, non-profit organization facilitating lifelong learning for health care providers and Chiesi, paid to institution; European Respiratory Society and Belgian Respiratory Society membership, member of faculty board and faculty committees. G. G. Brusselle reports payments of advisory boards and lecture fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline (GSK), Novartis, MerckSharp&Dohme (MSD) and Sanofi; President of the Belgian Respiratory Society. Other authors have no conflict of interest to disclose.